A Time Course of Bevacizumab (Anti-VEGF) Effect on Rat Peritoneum: Relations Between Antiadhesive Action and Fibrin Regulation Enzymes

Surg Innov. 2017 Dec;24(6):543-551. doi: 10.1177/1553350617729510. Epub 2017 Sep 7.

Abstract

Background: To investigate the early and late antiadhesive effect and any changes of fibrin matrix regulation enzymes on rat peritoneum, after local administration of bevacizumab.

Methods: Rats were subjected to cecal abrasion. Bevacizumab (5 mg/kg) against placebo was given intraperitoneally. On the 2nd, 14th, and 28th postoperative days adhesions were scored, and tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), matrix metalloproteinase-9 (MMP-9), degree of fibrosis, and angiogenesis were measured in abrased cecum and in intact parietal peritoneum.

Results: Bevacizumab significantly reduced adhesions up to 15% on the 2nd, 52.5% on the 14th, and 55% on the 28th postoperative day, and significantly increased tPA concentrations in peritoneum. PAI-1 was decreased, and a significantly higher tPA/PAI-1 ratio along with an increase of MMP-9 was measured at all time points. Fibrosis and angiogenesis were significantly lower on the 14th and 28th postoperative days.

Conclusions: Local bevacizumab administration has a strong early and late antiadhesive action on rat peritoneum, mediated by changes in the tPA/PAI-1 and MMP balance in favor of fibrinolysis up to 28 days after operations.

Keywords: bevacizumab; matrix metalloproteases; peritoneal adhesions; plasmin activator inhibitors; tissue plasmin activator; vascular endothelial growth factor.

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Animals
  • Bevacizumab / pharmacology*
  • Cecum / drug effects*
  • Cecum / pathology
  • Fibrinolysis / drug effects*
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Peritoneum / drug effects*
  • Peritoneum / pathology
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Rats
  • Rats, Wistar
  • Tissue Adhesions / prevention & control*
  • Tissue Plasminogen Activator / metabolism

Substances

  • Angiogenesis Inhibitors
  • Plasminogen Activator Inhibitor 1
  • Bevacizumab
  • Tissue Plasminogen Activator
  • Matrix Metalloproteinase 9